Apyx Medical announces Renuvion study shows significantly fewer adverse events vs InMode RF

Apyx Medical Corp

Retrospective study of 450+ patients: 229 Renuvion vs 236 InMode Bipolar RF; statistically fewer adverse events (p<.0001).
Adverse events included burns, hematoma, hypertrophic scar, and seroma; Renuvion group had significantly less.
Renuvion featured in three educational sessions at AACS 40th Annual Scientific Meeting, Feb 22-24, 2024.
Dr. Michael Kluska presents the study; CEO Charlie Goodwin highlights expansion of clinical evidence supporting safety.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.